Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.06%
#3 BankrCoin BankrCoin +20.27%
#4 MarsCoin MarsCoin +19.67%
#5 Ankr Network Ankr Network +18.93%
#6 Hive Hive +18.83%
#7 StonkBroker StonkBroker +14.43%
#8 Status Status +12.01%
#9 Prom Prom +11.13%
#10 Provenance Blockchain Provenance Blockchain +8.75%
Coin of the day
Palladium Network Palladium Network
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Classement en actions #18268
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Prix de l'action
$1.79
Dernière synchronisation: 2026-09-02
Capitalisation boursière
$205.75M
Changement (1 jour)
3.18%
Changement (1 an)
-61.61%
Pays
US
Échange NovaBridge Biosciences (NBP)

Catégorie

Healthcare
Bénéfices pour NovaBridge Biosciences (NBP)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de NovaBridge Biosciences, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour NovaBridge Biosciences de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH